Atrium Therapeutics Stock Forward View - Simple Regression
| RNADelisted Stock | USD 14.54 0.79 5.75% |
Momentum
Sell Peaked
Oversold | Overbought |
This section provides headline-driven context for Atrium Therapeutics Common alongside peer activity.
The Simple Regression forecasted value of Atrium Therapeutics Common on the next trading day is expected to be 33.74 with a mean absolute deviation of 14.42 and the sum of the absolute errors of 879.73.Atrium Therapeutics after-hype prediction price | $ 14.54 |
Hype signals are presented as complementary context to forecasting, technicals, analyst estimates, earnings, and momentum.
Atrium |
Atrium Therapeutics Additional Predictive Modules
Most predictive techniques to examine Atrium price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Atrium using various technical indicators. When you analyze Atrium charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Regression Price Forecast For the 17th of March 2026
Given 90 days horizon, the Simple Regression forecasted value of Atrium Therapeutics Common on the next trading day is expected to be 33.74 with a mean absolute deviation of 14.42 , mean absolute percentage error of 281.00 , and the sum of the absolute errors of 879.73 .Please note that although there have been many attempts to predict Atrium Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Atrium Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Atrium Therapeutics | Atrium Therapeutics Price Prediction | Research Analysis |
Forecasted Value
The next-day forecast for Atrium Therapeutics Common focuses on identifying predictive downside and upside bands that can frame a realistic trading range. The current forecast range spans downside near 23.37 and upside near 44.10.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Atrium Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Atrium Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 123.7489 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 14.4219 |
| MAPE | Mean absolute percentage error | 0.4554 |
| SAE | Sum of the absolute errors | 879.733 |
Mean reversion opportunities in Atrium Therapeutics' arise when market prices disconnect from fundamental anchors such as earnings, book value, or historical price-to-earnings multiples.
After-Hype Price Density Analysis
Using probability distributions for Atrium Therapeutics forecasting acknowledges that no model can consistently predict Atrium Therapeutics' exact future price. The distribution approach quantifies model uncertainty and helps investors avoid overconfidence in any single forecast.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The after-hype price analysis for Atrium Therapeutics provides a news-conditional view of potential price outcomes. Atrium Therapeutics' after-hype downside and upside margins for the prediction period are 4.26 and 24.82, respectively. This analysis complements technical and fundamental research by adding a news-sentiment dimension to Atrium Therapeutics' price forecasting.
Current Value
Macroaxis estimates the after-hype price of Atrium Therapeutics Common across a 3 months horizon to evaluate where the instrument could settle once headline distortion subsides. The objective is to separate event-driven enthusiasm from a more stable price path once the market absorbs the catalyst.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Atrium Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atrium Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Atrium Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.30 | 10.36 | 0.14 | 0.14 | 12 Events | 8 Events | In 12 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
14.54 | 14.54 | 0.00 |
|
Hype Timeline
On the 16th of March 2026 Atrium Therapeutics is traded for 14.54. The company has historical hype elasticity of 0.14, and average elasticity to hype of competition of 0.14. Atrium is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is estimated to be very small, whereas the daily expected return is at this time at -1.3%. %. The volatility of related hype on Atrium Therapeutics is about 9333.33%, with the expected price after the next announcement by competition of 14.68. About 92.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.19. Atrium Therapeutics had not issued any dividends in recent years. Considering the 90-day investment horizon the next estimated press release will be in 12 days. Use Historical Fundamental Analysis of Atrium Therapeutics to cross-verify projections for Atrium Therapeutics. The view supplies historical context for the projection discussion.Related Hype Analysis
The peer hype comparison table for Atrium Therapeutics includes downside risk metrics such as value-at-risk and maximum drawdown for Atrium Therapeutics' competitors. providing context for assessing the relative risk profile of a Atrium Therapeutics investment.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| JAZZ | Jazz Pharmaceuticals PLC | 5.34 | 8 per month | 2.00 | 0.06 | 1.85 | -3.95 | 17.22 | |
| MDGL | Madrigal Pharmaceuticals | -2.84 | 11 per month | 0.00 | -0.11 | 3.41 | -3.53 | 19.67 | |
| CAI | Caris Life Sciences | 0.74 | 9 per month | 0.00 | -0.17 | 3.53 | -6.33 | 17.67 | |
| MRNA | Moderna | 0.30 | 9 per month | 3.22 | 0.22 | 10.85 | -5.95 | 23.89 | |
| MRUS | Merus BV | -0.06 | 7 per month | 0.60 | 0.12 | 0.51 | -0.23 | 36.44 | |
| ABVX | Abivax SA American | 3.66 | 9 per month | 3.72 | 0.03 | 6.20 | -6.57 | 29.38 | |
| CYTK | Cytokinetics | -0.56 | 4 per month | 0.00 | -0.01 | 3.98 | -3.95 | 15.74 | |
| NUVL | Nuvalent | -2.83 | 9 per month | 0.00 | -0.03 | 2.93 | -3.90 | 15.70 | |
| TECH | Bio Techne Corp | -2.67 | 7 per month | 0.00 | -0.08 | 3.56 | -4.01 | 12.41 | |
| RYTM | Rhythm Pharmaceuticals | 0.03 | 41 per month | 0.00 | -0.06 | 4.55 | -5.14 | 18.69 |
Other Forecasting Options for Atrium Therapeutics
The movement of Atrium price is the central consideration for investors deciding whether to enter or hold a position. Noise in Atrium Stock price charts can make it difficult to distinguish meaningful trends from random fluctuations.Atrium Therapeutics Related Equities
The following equities are related to Atrium Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Atrium Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Atrium Therapeutics Market Strength Events
Investors use market strength indicators for Atrium Therapeutics to evaluate how the stock performs relative to broader market trends. These indicators support more precise timing of Atrium Therapeutics Common positions, helping investors maximize return and minimize poorly-timed trades.
Atrium Therapeutics Risk Indicators
A careful analysis of Atrium Therapeutics' basic risk indicators helps investors understand the risk environment surrounding atrium stock. This understanding is an essential input for forecasting Atrium Therapeutics' future price and for deciding how to manage the associated investment risk.
| Mean Deviation | 2.65 | |||
| Standard Deviation | 9.91 | |||
| Variance | 98.28 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Atrium Therapeutics
Coverage intensity for Atrium Therapeutics Common matters because narrative visibility can influence sentiment, participation, and volatility around the name. This is most useful when investors want to understand why a security is suddenly drawing more public discussion.
Contributor Headline
Latest Perspective From Macroaxis
Atrium Therapeutics Short Properties
Reviewing short-oriented indicators for Atrium Therapeutics Common is useful because long and short participants often create very different signals for timing and volatility. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 137.7 M | |
| Cash And Short Term Investments | 1.7 B |
Use Historical Fundamental Analysis of Atrium Therapeutics to cross-verify projections for Atrium Therapeutics. The view supplies historical context for the projection discussion. Atrium Therapeutics currently shows ROE of -43.98%, market cap of 11.24 Billion. This analysis of Atrium Therapeutics works best as a complementary layer when evaluating how the security fits in a broader portfolio. The supplemental views below help investors decide how Atrium Therapeutics complements or overlaps with existing portfolio holdings. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Atrium Stock
Atrium Therapeutics liquidity profile may be thinner following delisting.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |